Kabi Awaits Melrose Park Fate As mAbxience Deal Closes

€455m Deal For 55% Stake In Biosimilars Business Closed 1 August

 
• By Dean Rudge
  
NicoElNino/Alamy Stock Photo
Kabi now holds a 55% stake in mabxience • Source: Shutterstock (NicoElNino / Alamy Stock Photo/Alamy Stock Photo)
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products